WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Nicole LabrosseSVP CHIEF FINANCIAL OFFICER2026-02-162,747$79.44
$218.22kSell
Mark Howard SnyderSVP CHIEF LEGAL OFFICER2026-02-166,481$79.44
$514.85kSell
Helen TorleyPRESIDENT AND CEO2026-02-169,104$79.44
$723.22kSell
Helen TorleyPRESIDENT AND CEO2026-02-1611,334$79.44
$900.37kSell
Helen TorleyPRESIDENT AND CEO2026-02-1627,605$79.44
$2.19MSell
Mark Howard SnyderSVP CHIEF LEGAL OFFICER2026-02-162,587$79.44
$205.51kSell
Nicole LabrosseSVP CHIEF FINANCIAL OFFICER2026-02-167,273$79.44
$577.77kSell
Nicole LabrosseSVP CHIEF FINANCIAL OFFICER2026-02-162,874$79.44
$228.31kSell
Helen TorleyPRESIDENT AND CEO2026-02-054,624$78.94
$365.00kSell
Helen TorleyPRESIDENT AND CEO2026-02-055,376$78.38
$421.37kSell

1 of 12

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk22.65%26,633,924$2.12BInsider
Blackrock Inc11.19%13,153,857$1.04BInstitution
Vanguard Group Inc9.84%11,566,896$918.87MInstitution
State Street Corp4.36%5,121,672$406.87MInstitution
Gregory Ian Frost3.10%3,641,380$289.27MInsider
Arrowstreet Capital Limited Partnership2.74%3,222,507$256.00MInstitution
Morgan Stanley2.26%2,658,299$211.18MInstitution
Geode Capital Management LLC2.07%2,433,193$193.29MInstitution
Snyder Capital Management L P2.04%2,399,188$190.59MInstitution
Dimensional Fund Advisors LP1.79%2,104,157$167.15MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO73.39%26.61%Net SellingNet Selling
AXSM47.39%45.76%Net SellingNet Buying
ABVX27.07%0.00%
TECH75.07%2.49%Net BuyingNet Selling
ARWR54.65%9.85%Net SellingNet Selling
View Top Biotech Stocks

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 81.01% institutional shareholders, 29.37% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 22.57% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $2.14B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.